Recruiting studies: Non Small Cell Lung Cancer With Mutation In Epidermal Growth

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Phase 1/1b Study of IAM1363 in HER2 Cancers
Phase 1 · 53 location(s) · Iambic Therapeutics, Inc · NCT06253871 Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge
Phase 2 · 10 location(s) · Mark Vincent · NCT04335292 Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Phase 1/Phase 2 · 66 location(s) · Genmab · NCT05579366 A Phase l Clinical Study to Evalute the Safety,Tolerability,Pharmacokinetic Characteristics,and Preliminary Anti-tumor E
Phase 1 · 1 location(s) · Tongji University · NCT07361237 A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doub
Phase 3 · 303 location(s) · AstraZeneca · NCT06417814 Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Li
Phase 3 · 78 location(s) · ArriVent BioPharma, Inc. · NCT07185997 Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer Aft
Phase 2/Phase 3 · 186 location(s) · Bristol-Myers Squibb · NCT07100080 A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced o
Phase 3 · 1 location(s) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · NCT07183189 Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced
Phase 3 · 166 location(s) · AstraZeneca · NCT06350097 A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGF
NA · 1 location(s) · Kunming Medical University · NCT06102928 A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC
Phase 2 · 1 location(s) · Sichuan University · NCT06951464 A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer
Phase 1/Phase 2 · 29 location(s) · Voronoi, Inc · NCT07699328 Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
Phase 1/Phase 2 · 10 location(s) · Genprex, Inc. · NCT04486833 Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA
Phase 2 · 26 location(s) · Sun Yat-sen University · NCT05334277 A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Particip
Phase 3 · 285 location(s) · Bayer · NCT06452277 Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib or Sacituzumab Tirumotecan for Neoadjuvant Tre
Phase 2 · 1 location(s) · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · NCT07329322 A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alon
Phase 1/Phase 2 · 67 location(s) · BioNTech SE · NCT07070232 A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
Phase 1 · 6 location(s) · EpiBiologics · NCT07462377 JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study
Phase 2 · 2 location(s) · Shanghai Junshi Bioscience Co., Ltd. · NCT07518160 A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal
Phase 3 · 1 location(s) · Allist Pharmaceuticals, Inc. · NCT06970639 Boosting Osimertinib Blood Brain Barrier Penetration
Phase 2 · 2 location(s) · Maastricht University Medical Center · NCT07485452 To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mut
Phase 3 · 1 location(s) · Allist Pharmaceuticals, Inc. · NCT04853342 To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Posi
Phase 2 · 1 location(s) · Juan LI, MD · NCT06192849 A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC
Phase 2 · 1 location(s) · Shanghai Chest Hospital · NCT07058519 A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients
Phase 3 · 1 location(s) · Shanghai JMT-Bio Inc. · NCT06735391 An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Pat
Phase 4 · 39 location(s) · AstraZeneca · NCT07357597 A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult
Phase 1/Phase 2 · 61 location(s) · Bristol-Myers Squibb · NCT06618287 A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR
Phase 2 · 80 location(s) · Taiho Oncology, Inc. · NCT05967689 Bolstering Outcomes After Induction With Osimertinib Plus Chemotherapy Through Optimized Site-Directed Primary Tumor The
Phase 2 · 1 location(s) · Pusan National University Hospital · NCT07073365 First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations i
Phase 1/Phase 2 · 94 location(s) · Bayer · NCT05099172

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →